Primary:

Change of volume of perihematomal edema as assessed by brain CT.

Secondary:

The change of ICH volume between the initial and the follow-up CT scans The neurological status at 90 day using E-GOS and mRS. The cumulative incidence of major and minor adverse events that occurred during and after hospitalization until the end of the study

1. INCLUSION/EXCLUSION CRITERIA

   1. Inclusion Criteria

      • Spontaneous intracerebral hemorrhage was documented by CT scanning within 24 hours of the onset of symptoms
      • Supratentorial location of hemorrhage
      • Older than 17 yrs
      • Informed consent before study

   2. Exclusion Criteria

      • Planned surgical evacuation of hematoma within 24hrs
      • Secondary ICH such as trauma or aneurysmal rupture
      • Taking anticoagulation previously
      • Pregnancy,known allergy to celecoxib, severe liver or kidney disease, or poor performance state were excluded
      • Other physical condition, making the patient difficult to participate in this study (decided by the neurologist or the physician).

2. OTHER THERAPY

   -No limitation of other medications except NSAIDs, anticoagulation and antiplatelet agent because of aggravating the symptoms

3. STUDY DESIGN Multicenter, prospective randomized, comparative open with blinded endpoints (PROBE) trial to assess the safety and effectiveness of administration of celecoxib for 14 days in patients with intracerebral hemorrhage

Inclusion Criteria:

1. Spontaneous intracerebral hemorrhage was documented by CT scanning within 24 hours of the onset of symptoms
2. Supratentorial location of hemorrhage
3. Older than 17 yrs

Exclusion Criteria:

1. Planned surgical evacuation of hematoma within 24hrs
2. Secondary ICH due to trauma or aneurismal rupture or etc
3. Taking antithrombotics or other NSAIDs previously
4. Pregnancy
5. Other physical condition, making the patient difficult to participate the study (decided by the neurologist or the physician).